Capital Asset Advisory Services LLC Sells 509 Shares of Shire PLC (SHPG)
Capital Asset Advisory Services LLC cut its stake in shares of Shire PLC (NASDAQ:SHPG) by 17.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,480 shares of the biopharmaceutical company’s stock after selling 509 shares during the period. Capital Asset Advisory Services LLC’s holdings in Shire were worth $385,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in SHPG. Harding Loevner LP grew its stake in Shire by 18,894.4% in the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after acquiring an additional 126,865,607 shares during the period. Janus Henderson Group PLC boosted its position in shares of Shire by 22,560.3% during the second quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock worth $212,683,000 after buying an additional 1,281,202 shares during the period. Third Point LLC acquired a new position in shares of Shire during the third quarter worth about $183,768,000. Glenview Capital Management LLC boosted its position in shares of Shire by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares during the period. Finally, Sterling Capital Management LLC boosted its position in shares of Shire by 26,182.4% during the third quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock worth $72,649,000 after buying an additional 472,592 shares during the period. 20.19% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently weighed in on SHPG shares. ValuEngine raised Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 target price on shares of Shire in a report on Sunday, October 8th. Royal Bank of Canada reiterated a “buy” rating and set a $213.00 target price on shares of Shire in a report on Monday, October 2nd. Cantor Fitzgerald reiterated a “buy” rating and set a $222.00 target price on shares of Shire in a report on Thursday, September 14th. Finally, FBR & Co began coverage on Shire in a report on Thursday, October 19th. They set a “buy” rating and a $201.00 target price on the stock. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $212.18.
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the company earned $3.17 EPS. sell-side analysts predict that Shire PLC will post 15 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/capital-asset-advisory-services-llc-sells-509-shares-of-shire-plc-shpg/1803167.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.